ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
IPO

Chinese COVID vaccine maker Clover Biopharma set for HKEX debut

Company aims to win regulatory approval and begin shipments to COVAX by year-end

Development of Clover's COVID vaccine was financed by a grant worth up to $360.5 million from CEPI.    © Reuters

SHANGHAI -- China's Clover Biopharmaceuticals is set to debut on the Stock Exchange of Hong Kong on Friday as it races to win regulatory approval and begin shipments of its COVID-19 vaccine.

Though founded in 2007, Chengdu-based Clover has yet to generate any operating revenue. Development of its COVID vaccine was financed by a grant worth up to $360.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI), the disease research funding group set up by the Gates Foundation, Japan, the EU and other governments.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more